Comparative Pharmacology
Head-to-head clinical analysis: CLIMARA versus DIETHYLSTILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLIMARA versus DIETHYLSTILBESTROL.
CLIMARA vs DIETHYLSTILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol replacement therapy; binds to estrogen receptors, activating gene transcription leading to estrogenic effects in target tissues.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Transdermal, 0.025-0.1 mg/day applied once weekly; start with lowest effective dose. Adjust based on clinical response.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
None Documented
None Documented
Terminal elimination half-life is approximately 13–17 hours for estradiol via transdermal route, supporting once-weekly dosing.
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: 20-30%.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."